Cartesian Therapeutics ($RNAC) has announced several significant developments. The company reported positive topline results from a Phase 2b trial of Descartes-08 in patients with Myasthenia Gravis. Additionally, Cartesian Therapeutics has dosed the first patient in a Phase 2 trial of Descartes-08 for treating Systematic Lupus Erythematosus. Furthermore, the company has secured $130 million in private placement equity financing.
📰 AUTO-IMMUNE UPDATE: BCMA CART in MG $RNAC https://t.co/Jg0ExzulUm
$RNAC - the biggest issue "to me" is what happen to the data from the non-academic center cohort - why were the #s there not available - .. for MG, I like to see at least 3 mos, ideally 6 mos worth of data - .. on the generous side of data interpretation - there is some efficacy…
$RNAC https://t.co/oIZ49xEkyz
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing $RNAC https://t.co/UjfozKPf7f
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus $RNAC https://t.co/E2NKweVtvl
Positive Ph.2b MG data + $130mn PIPE + dosed first patient in SLE study $RNAC https://t.co/Je2Ecvyxp0
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis $RNAC https://t.co/zvN7ssmGmG
$RNAC Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis. https://t.co/xoHwp0kDyj